20 August 2008

Lifeline Scientific, Inc
("Lifeline" or "the Company")

Further Results from Machine Preservation Trial

LifePort Kidney Transporter demonstrates clear advantages over traditional ice box storage for kidney transplants

Lifeline Scientific, the medical technology company, announces further data from the Machine Preservation Trial comparing the LifePort® Kidney Transporter ("LifePort") with the standard practice of static storage using ice in a cool box. These data were presented last week at the XXII International Congress of the Transplantation Society in Sydney, Australia.

The results demonstrate for the first time that kidneys from non-heart beating donors and from older donors are more likely to function immediately post transplantation when preserved with the LifePort Kidney Transporter than kidneys stored in the standard way. Non heart beating and older donors represent a significant potential new resource to help solve the global shortage of donor organs for transplant. A transplant patient who receives a kidney that does not work immediately will need to receive post–transplant dialysis treatment. Kidneys with delayed graft function (DGF) are also associated with an increased risk of organ rejection and greater costs to the healthcare system.

Highlights of the Results

- Statistically significant results showed that DGF was strongly reduced in transplanted kidneys from non-heart beating donors by using LifePort

- Primary non-function (complete failure immediately post transplant) of transplanted kidneys from older donors was significantly reduced when those kidneys were preserved using LifePort

- When DGF did occur after transplantation of kidneys from older deceased donors, six month graft survival was significantly better in kidneys preserved with LifePort

The trial was conducted in conjunction with Eurotransplant and Deutsche Stiftung Organ transplantation.

David Kravitz, Chief Executive of Lifeline Scientific, said:

"These results further demonstrate the advantages of LifePort over the traditional static ice box storage. LifePort has the potential to not only help improve the quality and number of kidneys available for transplantation but also improve outcomes for kidney transplant recipients and reduce the overall costs of kidney transplants."

Enquiries

Lifeline Scientific, Inc.	
David Kravitz, CEO	
Seymour Pierce (Nomad)	**+44 (0)20 7107 8000**
Mark Percy / Huaizheng Peng / Sarah Jacobs	
Financial Dynamics	**+44 (0)20 7831 3113**
Ben Brewerton / John Dineen	

Detailed Results

1. Machine perfusion versus cold storage preservation in non-heart-beating kidney donation and transplantation

This analysis of the Machine Preservation Trial compared outcomes in 82 pairs of kidney from non heart-beating-donors, which were assigned to either machine preservation (MP) with the LifePort or to conventional cold storage (CS). All 164 recipients were followed up at three months post transplantation. Statistically significant results showed that delayed graft function (DGF) was strongly reduced. (Duration of DGF [days] was 9 in MP vs. 13 in CS p=0.05. DGF < 7 days occurred in 27% in the MP vs. 10.5% in the CS arm, p=0.028).

2. Machine perfusion versus cold storage in transplantation of kidneys from older deceased donors: results of a prospective randomized multicenter trial

A second analysis compared 118 pairs of kidneys from donors 55 years old and older which were randomly assigned to either machine preservation or cold storage. All 236 recipients were followed up at 6 months. Although this trial utilised expanded criteria organs and DGF did occur in both MP and CS group (with the incidence of DGF 22% in MP vs.31.4 % in CS recipients, p=0.07), the trial demonstrated that the function of MP kidneys recovered faster that those in the CS group(DGF <7 days occurred in 10 recipients, in the MP vs. 5 in the CS arm, p=0.02). When DGF occurred six month graft survival was significantly better in kidneys preserved with MP than by CS: 84% vs. 60%, p=0.026.

In addition this trial demonstrated statistically significant results in favour of MP in respect of primary non function (2.5% in MP vs. 10.2% in CS kidney recipients P=0.015).

About the Machine Preservation Trial

The Machine Preservation Trial is the first prospective, statistically powered, randomized, controlled, multicentre trial to investigate the efficacy, cost effectiveness and practicalities of continuous hypothermic machine perfusion from donor to recipient versus static storage in deceased donor kidneys. The trial lasted for two years.

The Machine Preservation Trial was conducted in collaboration with Eurotransplant and the Deutsche Stiftung Organtransplantation ("DSO"). Since 1 November 2005, all cadaveric kidney donors over 16 years of age from Belgium, The Netherlands, and the DSO Region Nordrhein-Westfalen Germany were considered for enrollment in the trial. The trial was sponsored by Organ Recovery Systems, an operating business of Lifeline Scientific.

The trial compared outcomes in 338 pairs of kidneys, one preserved with machine preservation on the LifePort and the other by static ice box storage. .

About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. During its pilot introduction, over 230 LifePorts have been installed in 75 transplant programmes worldwide treating more than 12,000 kidneys.

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is to commercialise its FDA approved, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. Devices for preservation of the heart, lung pancreas and liver are in late stage pre-clinical development.